by Jordana Choucair | Jan 28, 2022 | Life Sciences
Merck & Co. Inc. and Ridgeback Biotherapeutics LP said their COVID-19 antiviral pill, molnupiravir, was active against the Omicron variant in six lab studies. The drug’s effectiveness against Omicron hasn’t yet been studied in human trials. (Article...
by Jordana Choucair | Jan 28, 2022 | Life Sciences
Biogen Inc. will sell its nearly 50 percent stake in Samsung Bioepis, a joint venture with Samsung Biologics to develop biosimilar drugs, to its partner for at least $2.25 billion. The deal will give Biogen access to $1 billion in cash upon closing as the pharma...
by Jordana Choucair | Jan 27, 2022 | Payers
During a recent webinar, Third Horizon Strategies Managing Director Cheryl Matochik discussed what the employee benefits industry can expect to see in 2022. Cheryl stated that the industry is “moving toward a completely new standard of personalized benefits.” She, and...
by Jordana Choucair | Jan 27, 2022 | Transition to Value
The CMS announced that 66 new ACOs joined the Medicare Shared Savings Program (MSSP) and 140 existing ACOs renewed their participation for a new agreement period starting January 1, 2022. This brings the total number of ACOs in the MSSP to 483 in 2022, up slightly...
by Jordana Choucair | Jan 27, 2022 | Mental Health
Numerous reports and studies have highlighted the importance of employers offering mental health support to employees. Doing so not only increases employee engagement and productivity, but reduces direct and indirect costs. A new blog authored by Cheryl Matochik...
by Jordana Choucair | Jan 27, 2022 | Life Sciences
The Biden administration redirected nearly $7 billion from an emergency relief fund for health care providers in order to buy COVID-19 vaccines and treatments, leaving the emergency fund nearly empty. A spokesperson HHS defended the decision, saying it was a...
Recent Comments